Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Accumulated Expenses (2017 - 2025)

Serina Therapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $1.4 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses rose 10892.31% year-over-year to $1.4 million; the TTM value through Dec 2024 reached $1.4 million, up 10892.31%, while the annual FY2024 figure was $1.4 million, 10892.31% up from the prior year.
  • Accumulated Expenses for Q4 2024 was $1.4 million at Serina Therapeutics, up from $449000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.4 million in Q4 2024 and bottomed at $13000.0 in Q4 2023.
  • The 5-year median for Accumulated Expenses is $199000.0 (2023), against an average of $362866.7.
  • The largest annual shift saw Accumulated Expenses tumbled 93.26% in 2023 before it skyrocketed 10892.31% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $228000.0 in 2020, then fell by 7.02% to $212000.0 in 2021, then decreased by 8.96% to $193000.0 in 2022, then crashed by 93.26% to $13000.0 in 2023, then surged by 10892.31% to $1.4 million in 2024.
  • Per Business Quant, the three most recent readings for SER's Accumulated Expenses are $1.4 million (Q4 2024), $449000.0 (Q2 2024), and $1.3 million (Q1 2024).